Verbatim response from ChatGPT
Short answer: probably not — avoid compounded “GLP‑1 drops/tablets.” Use FDA‑approved products (or a prescriber‑supervised program) instead.
Why:
- Most GLP‑1 drugs are peptides that are destroyed by stomach acid/enzymes and/or don’t cross the gut lining well. Approved oral semaglutide (brand: Rybelsus) is effective because it uses a specific absorption enhancer (SNAC) and was tested in clinical trials. Compounded drops/tablets generally do not replicate that formulation or have clinical proof of absorption/effectiveness.
- Injectable GLP‑1 receptor agonists (examples: Ozempic and Wegovy — semaglutide by Novo Nordisk; Trulicity — dulaglutide by Lilly; Mounjaro and Zepbound — tirzepatide by Lilly) have robust randomized‑trial evidence for blood‑sugar lowering and/or weight loss and known dosing/bioavailability.
- Compounded oral/sublingual GLP‑1 products are largely untested in controlled studies. Stability, dose accuracy, and bioavailability are uncertain. That means you may get little or no drug effect — or unpredictable effects — and you lose the safety/efficacy guarantees of approved products.
Safety/regulatory concerns:
- Compounded drugs aren’t FDA‑approved and quality varies between pharmacies. Look for a PCAB‑accredited compounding pharmacy and request certificates of analysis, but that does not equal the evidence from clinical trials.
- Risks include contamination, incorrect dosing, unknown potency, and unexpected side effects. There’s also potential interaction with other medicines and risks such as nausea, pancreatitis risk signals, gallbladder issues, and hypoglycemia when combined with other diabetes drugs.
If you’re considering an oral option:
- Talk to your clinician about FDA‑approved oral semaglutide (Rybelsus). It has specific dosing rules (take on an empty stomach with a small amount of water, wait ~30 minutes before eating/other meds) because bioavailability is low and timing matters.
- If injectables are a concern, discuss available injectables (Ozempic/Wegovy — semaglutide; Mounjaro/Zepbound — tirzepatide; Trulicity — dulaglutide; Victoza/Saxenda — liraglutide) and delivery devices. Many people tolerate pens well; some clinics offer teaching/support to reduce injection anxiety.
- If cost/access is the issue, ask about manufacturer patient‑assistance programs or authorized discount programs rather than turning to unproven compounded products.
Bottom line: only one oral GLP‑1 is FDA‑approved (Rybelsus) and is effective because of a specific formula and clinical testing. Compounded oral “drops/tablets” lack reliable evidence and carry quality/safety risks. Discuss safer, proven options with your prescriber.